Decision of adjuvant chemotherapy in intermediate risk luminal breast cancer patients: A prospective multicenter trial assessing the clinical and psychological impact of EndoPredict® (EpClin) use (UCBG 2-14).

Frédérique Penault-Llorca,Fabrice Kwiatkowski,Antoine Arnaud,Christelle Levy,Marianne Leheurteur,Lionel Uwer, Olfa Derbel, Annick Le Rol,Jean-Philippe Jacquin,Christelle Jouannaud,Nathalie Quenel-Tueux, Véronique Girre,Cyril Foa,Emmanuel Guardiola,Alain Lortholary,Stéphanie Catala,Séverine Guiu,Alexander Valent,Diane Boinon,Jérome Lemonnier,Suzette Delaloge

The Breast（2020）

Cited 19|Views24

No score

Abstract

•EndoPredict ® (EpClin) allowed a chemotherapy decision modification in 35% of the patients included in the Adendom trial.•Patient-physician concertation is important: 8% of treatment changes are based on patients’ will.•A single-step decision including the test appears preferable to limit anxiety and distress.

Translated text

Key words

Breast cancer,Genomic test,Chemotherapy,Patient reported outcomes,EndoPredict®

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined